Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Signals Found to Preserve Antiviral Antibodies

September 2, 2011 6:21 am | News | Comments

Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been encountered and defeated.


New HIV Vax Targets Desirable Immune Cells

September 2, 2011 6:10 am | News | Comments

Researchers have demonstrated an approach to HIV vaccine design that uses an altered form of HIV's outer coating or envelope protein. The design could bind better to immature B cell receptors creating an enhanced immune response.


More Extensions in Pfizer's Icagen Bid

September 2, 2011 6:04 am | News | Comments

Drugmaker Pfizer Inc. for a second time is extending its tender offer for pain drug developer Icagen, as the number of shares tendered again fell short of what Pfizer needed.


Dendritic Cells Protect Against Acetaminophen

September 2, 2011 5:59 am | News | Comments

Researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults and children.


Sanofi to Sell Generic Lipitor in France

September 1, 2011 12:30 pm | News | Comments

French drugmaker Sanofi SA will begin selling a generic version of Pfizer's Lipitor, at nearly $11 billion a year starting in the spring of 2012.


Selecta Biosciences Awarded Subcontract for Malaria Vaccine

September 1, 2011 12:26 pm | News | Comments

Selecta Biosciences, Inc. announced that Science Applications International Corporation (SAIC) awarded them a subcontract to develop a targeted synthetic vaccine particle product for malaria.


Research Shows Aspirin Has Few Short-Term Effects

September 1, 2011 12:20 pm | News | Comments

A meta-analysis reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.


Genome Wide Association Study Overcomes Limitations

September 1, 2011 12:08 pm | News | Comments

Metabolon, Inc.’s study, “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” establishes the strong association of biochemical levels with the genetics of an individual and illustrates the power of combining metabolomics with genomics analyses.


Bioprocess Analyzer

September 1, 2011 8:13 am | Drug Discovery & Development | Product Releases | Comments

The Cedex Bio Bioprocess Analyzer from Roche is a continuous random-access analyser, enabling for a safe and reliable determination of chemical and biochemical parameters in aqueous solutions.


Digital Dispenser

September 1, 2011 8:10 am | Product Releases | Comments

Tecan has launched the HP D300 Digital Dispenser, a standalone instrument for the pharmaceutical sector, which uses HP Direct Digital Dispensing technology to rapidly deliver picoliter to microliter volumes of drug compounds.


HemoShear Wins $4.3M SBIR Grant

September 1, 2011 8:03 am | News | Comments

HemoShear, LLC announced that it has been awarded up to $4.3 million in a Phase 1 Small Business Innovation Research grant award from the National Heart, Lung and Blood Institute of the National Institutes of Health.


Saliva Test for Cancer Moves Closer

September 1, 2011 7:54 am | News | Comments

A new saliva test can measure the amount of potential carcinogens stuck to a person's DNA, interfering with the action of genes involved in health and disease, and could lead to a commercial test to help determine risks for cancer and other diseases.


MorphoSys Doses First Patient in Phase 1/2a Trial

September 1, 2011 7:49 am | News | Comments

MorphoSys AG announced that the first patient in a Phase 1/2a clinical trial of its cancer antibody MOR202 has been dosed. MOR202 is directed against a therapeutic target which is highly expressed in blood cancers.


DSMB Clears ReNeuron for Higher ReN001 Dose

September 1, 2011 7:38 am | News | Comments

ReNeuron Group reports that the Data Safety Monitoring Board for the Phase 1 clinical trial of its ReN001 stem cell therapy for stroke patients has recommended that the trial advances to the evaluation of a higher dose of ReN001.


Virus Successfully Targets Human Tumors

September 1, 2011 7:26 am | News | Comments

Researchers have reported results from a trial that showed that an intravenously-delivered viral therapy can consistently infect and spread within tumors without harming normal tissues in humans.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.